Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 2/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL105091 | 0.83 | TTK (0.39) | TTKSIRT6KDM4EMEN1KMT2A | |
| SCHEMBL8427840 | 0.71 | TTK (0.34) | TTKKDM4EMEN1KMT2A | |
| SCHEMBL105081 | 0.71 | TTK (0.40) | TTK | |
| SCHEMBL104534 | 0.70 | TTK (0.39) | TTKKDM4EMEN1KMT2A | |
| SCHEMBL105472 | 0.69 | TTK (0.76) | TTK | |
| SCHEMBL14536738 | 0.66 | TLR7 (0.36) | — | |
| SCHEMBL137874 | 0.65 | GAA (0.44) | TTKKDM4EMEN1KMT2A | |
| SCHEMBL16506085 | 0.64 | LMNA (0.33) | SIRT6KDM4E | |
| SCHEMBL13693181 | 0.63 | TTK (0.31) | TTK | |
| SCHEMBL9005123 | 0.62 | KDM4E (0.43) | KDM4EPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | TTK 6/4885SIRT6 3799/4885KDM4E 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.